Form 4: Bone Biologics CFO Deina Walsh Reports Stock Option Grant and Acquisition
SEC Form 4 Filing
Chief Financial Officer of Bone Biologics Corp, Deina Walsh, reports the acquisition of 27,055 stock options and 1,875 common stock.
Summary
- Deina Walsh, the Chief Financial Officer of Bone Biologics Corp, filed a Form 4 disclosing changes in beneficial ownership.
- The report details the acquisition of 27,055 employee stock options with an exercise price of $0.9678, which vest immediately.
- Additionally, 1,875 shares of common stock were acquired.
- The report also notes existing fully vested options for 12,500 shares at $3.61 and 78 shares at $57.6.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction, but the acquisition of options and shares by the CFO is a positive sign of confidence in the company.
Positives
- The acquisition of stock options and shares by the CFO indicates confidence in the company's future performance.
- The immediate vesting of the 27,055 options suggests a strong incentive for the CFO to contribute to the company's success.
Industry Context
This filing is a routine disclosure of stock option grants and share acquisitions by a company executive, which is common practice in publicly traded companies to align management interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard form of compensation for executives in publicly traded companies, aligning their interests with those of shareholders.
- The vesting schedule of the options is typical, with some vesting immediately and others vesting over time.
- The exercise prices of the options are set at different levels, which is common practice to incentivize performance at different stages of the company's growth.
Stakeholder Impact
- The acquisition of stock options and shares by the CFO could be viewed positively by shareholders, as it aligns management's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 01/15/2025 | Date of earliest transaction and the date the 27,055 options become exercisable. |
| 01/15/2027 | Expiration date of the 27,055 stock options. |
| 01/17/2025 | Date of the report. |
| 01/17/2026 | Date of existing fully vested options for 12,500 shares at $3.61. |
| 01/25/2025 | Date of existing fully vested options for 78 shares at $57.6. |
Keywords
stock options, Form 4, beneficial ownership, Bone Biologics Corp, Deina Walsh, CFO, equity incentive plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.